Karyopharm因子宫内膜癌临床试验未达预期而股价创下历史新低

路透中文08-01 01:45

BUZZ-Karyopharm因子宫内膜癌临床试验未达预期而股价创下历史新低

7月31日 - ** Karyopharm Therapeutics（KPTI.O）股价下跌71.9%，跌至1.97美元的历史最低点

** 股价跌破2025年8月创下的3.65美元的52周低点

** 该公司周四晚间表示，其用于治疗晚期或复发性子宫内膜癌的维持治疗药物塞利内索（selinexor），在一项晚期临床试验中未能实现显著改善无进展生存期的主要目标

** 公司表示，接受塞利内索治疗的患者无疾病进展的中位生存期为12.75个月，而安慰剂组为7.43个月，但该差异在统计学上不显著

** 该公司表示将减少对子宫内膜癌领域的投资，并将更多精力集中于骨髓纤维化和多发性骨髓瘤项目

** 若跌势持续，该股将创下有史以来最差单日表现

** 计入当日跌幅，该股今年以来累计下跌73%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2656739393?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-01 01:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2656739393","market":"hk","top_or_hot":-1,"title":"Karyopharm因子宫内膜癌临床试验未达预期而股价创下历史新低","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Karyopharm因子宫内膜癌临床试验未达预期而股价创下历史新低</title></head><body><p><span>7月31日</span><span> - </span>** Karyopharm <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>（<span>KPTI.O</span>）股价下跌71.9%，跌至1.97美元的历史最低点</p><p>** 股价跌破2025年8月创下的3.65美元的52周低点</p><p>** 该公司周四晚间表示，其用于治疗晚期或复发性子宫内膜癌的维持治疗药物塞利内索（selinexor），在一项晚期临床试验中未能实现显著改善无进展生存期的主要目标</p><p>** 公司表示，接受塞利内索治疗的患者无疾病进展的中位生存期为12.75个月，而安慰剂组为7.43个月，但该差异在统计学上不显著</p><p>** 该公司表示将减少对子宫内膜癌领域的投资，并将更多精力集中于骨髓纤维化和多发性骨髓瘤项目</p><p>** 若跌势持续，该股将创下有史以来最差单日表现</p><p>** 计入当日跌幅，该股今年以来累计下跌73%</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Karyopharm因子宫内膜癌临床试验未达预期而股价创下历史新低</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKaryopharm因子宫内膜癌临床试验未达预期而股价创下历史新低\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-08-01 01:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Karyopharm因子宫内膜癌临床试验未达预期而股价创下历史新低</title></head><body><p><span>7月31日</span><span> - </span>** Karyopharm <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>（<span>KPTI.O</span>）股价下跌71.9%，跌至1.97美元的历史最低点</p><p>** 股价跌破2025年8月创下的3.65美元的52周低点</p><p>** 该公司周四晚间表示，其用于治疗晚期或复发性子宫内膜癌的维持治疗药物塞利内索（selinexor），在一项晚期临床试验中未能实现显著改善无进展生存期的主要目标</p><p>** 公司表示，接受塞利内索治疗的患者无疾病进展的中位生存期为12.75个月，而安慰剂组为7.43个月，但该差异在统计学上不显著</p><p>** 该公司表示将减少对子宫内膜癌领域的投资，并将更多精力集中于骨髓纤维化和多发性骨髓瘤项目</p><p>** 若跌势持续，该股将创下有史以来最差单日表现</p><p>** 计入当日跌幅，该股今年以来累计下跌73%</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL4S43X24R:1","article_id":"2656739393","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2656739393","pubTimestamp":1785519916,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-Karyopharm因子宫内膜癌临床试验未达预期而股价创下历史新低7月31日-** Karyopharm Therapeutics（KPTI.O）股价下跌71.9%，跌至1.97美元的历史最低点** 股价跌破2025年8月创下的3.65美元的52周低点** 该公司周四晚间表示，其用于治疗晚期或复发性子宫内膜癌的维持治疗药物塞利内索（selinexor），在一项晚期临床试验中未能实现显著改","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","KPTI":"Karyopharm Therapeutics Inc."},"translate_title":"Karyopharm Stock Hits Record Low as Endometrial Cancer Clinical Trial Misses Expectations","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KPTI":0.9},"content_text":"BUZZ-Karyopharm因子宫内膜癌临床试验未达预期而股价创下历史新低7月31日 - ** Karyopharm Therapeutics（KPTI.O）股价下跌71.9%，跌至1.97美元的历史最低点** 股价跌破2025年8月创下的3.65美元的52周低点** 该公司周四晚间表示，其用于治疗晚期或复发性子宫内膜癌的维持治疗药物塞利内索（selinexor），在一项晚期临床试验中未能实现显著改善无进展生存期的主要目标** 公司表示，接受塞利内索治疗的患者无疾病进展的中位生存期为12.75个月，而安慰剂组为7.43个月，但该差异在统计学上不显著** 该公司表示将减少对子宫内膜癌领域的投资，并将更多精力集中于骨髓纤维化和多发性骨髓瘤项目** 若跌势持续，该股将创下有史以来最差单日表现** 计入当日跌幅，该股今年以来累计下跌73%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2656739393","isCrawlerRequest":true}